Microsatellite instability (MSI) is characterized by high degree of polymorphism in microsatellite lengths due to deficiency in mismatch repair (MMR) system. MSI is associated with several tumor types and its status can be considered as an important indicator for patient prognosis. Conventional clinical diagnosis of MSI examines PCR products of a panel of microsatellite markers using electrophoresis (MSI-PCR), which is laborious, costly, and time consuming. We developed MSIpred, a python package for automatic MSI classification using a machine learning technology -support vector machine (SVM). MSIpred computes 22 features characterizing tumor somatic mutational load from mutation data in mutation annotation format (MAF) generated from paired tumor-normal exome sequencing data, subsequently using these features to predict tumor MSI status with a SVM classifier trained by MAF data of 1074 tumors belonging to four types. Evaluation of MSIpred on an independent testing set, MAF data of another 358 tumors, achieved overall accuracy of ≥98% and area under receiver operating characteristic (ROC) curve of 0.967. Further analysis on discrepant cases revealed that discrepancies were partially due to misclassification of MSI-PCR. Additional testing of MSIpred on non-TCGA data also validated its good classification performance. These results indicated that MSIpred is a robust pantumor MSI classification tool and can serve as a complementary diagnostic to MSI-PCR in MSI diagnosis.
Scientific RepoRtS | (2018) 8:17546 | DOI:10.1038/s41598-018-35682-z the development of next generation sequencing (NGS) technology, several computational tools utilizing NGS data were developed for MSI diagnosis. MSIsensor 10 and mSINGS 11 determine tumor MSI status by measuring prevalence of unstable microsatellite loci in paired tumor-normal sequencing data. These two tools showed good performance but they both require lots of computational resources since they directly examine aligned reads in BAM format. MSIseq, MOSAIC, and MIRMMR [12] [13] [14] utilize machine learning algorithms to predict MSI status. MSIseq and MOSAIC implemented decision tree classifiers for MSI classification depending on just a single feature derived from tumor somatic mutation information, which is prone to over-fit their training datasets. MIRMMR built a logistic regression classifier requiring both methylation and mutation information of genes belonging to MMR system. A recent study revealed that, in addition to MSI, MMR-deficient tumors also display relatively higher somatic mutational load 15 . Thus, it is a reasonable direction to predict tumor MSI status through tumor mutation information obtained by exome sequencing. Recently, mutation calling has become a routine analysis of paired tumor-normal sequencing data. Several different pipelines for mutation calling have been published [16] [17] [18] [19] [20] [21] . These pipelines typically create a file in mutation annotation format (MAF). MAF files provide somatic mutation information of tumors including single nucleotide mutations, micro-indels, and their detailed translational/regulatory effects (for example, missense, nonsense, and silence mutations) on annotated genes. In this study, we explored distributions of somatic mutational load in MSI-PCR termed MSI-H and non MSI-H (MSS and MSI-L) tumors using their corresponding MAF files obtained from The Cancer Genome Atlas (TCGA) Research Network 22 , and subsequently developed a python package, MSIpred, implementing a pan-tumor binary MSI classifier to predict MSI status from tumor MAF files.
Results

Distributions of somatic mutational load in MSS and MSI-H tumors. We calculated 22 features
characterizing somatic mutational load of 1432 tumors of four types (see Table 1 , COAD: colon adenocarcinoma, READ: rectal adenocarcinoma, STAD: stomach adenocarcinoma, and UCEC: uterine corpus endometrial carcinoma) using mutation data from tumor MAF files. Of all 22 features, 1-9, previously used by MSIseq 12 , describe a general type (single nucleotide variants or micro-indels) of a mutation. 10-22 describe detailed classification of a mutation based on its translational and/or regulatory effects, which can provide critical information about how deleterious a mutation is (see Supplementary Table S1 ). All of these 22 features displayed skewed distributions in total 1432 tumors (see Supplementary Fig. S1 ). As a recent study revealed that MSI-L tumors were consistent with MSS tumors in terms of their MSI burden 13 , we combined MSS and MSI-L tumors together, and denoted them as MSS in this study. Referring to tumor clinical data provided by TCGA, 1123 of 1432 tumors were determined as MSS using MSI-PCR, the other 309 tumors were determined as MSI-H (see Table 2 ). MSI-H tumors displayed significantly higher counts of mutations (both single nucleotide variants and micro-indels) per megabase than MSS tumors throughout exome sequences and in simple sequence repeat regions. MSI-H tumors also tended to possess more deleterious mutations, such as mutations causing shifts in open reading frames, missense mutations, and nonsense mutations (Fig. 1) . By pairing these 22 features, a clear separation between MSS tumors and MSI-H tumors can be observed (see Supplementary Fig. S2 ). Wilcoxon rank-sum tests of each of these 22 features between MSS and MSI-H tumors were performed, and results indicated that all these 22 features were differently distributed between MSS and MSI-H tumors.
Analysis of 22 features used for mutational load characterization. 1432 tumors were then randomly split into two datasets, training and testing, using 3:1 ratio within each tumor type. Accordingly, the training set incorporated 1074 tumors of all four types, and the testing set incorporated 358 tumors of four types. Detailed information about these two datasets were presented in Tables 1 and 2 . In order to gain some insights about the contributions of these features to MSI classification, we first trained a random forest classifier using all 22 features of 1074 tumors belonging to the training set. The importance scores of all these 22 features were then Analysis of discrepant cases. We further investigated somatic mutational load (characterized by afore- (Fig. 3b) . This result suggests that the MSI-PCR results might not be very accurate for these cases.
Validation of MSIpred using non-TCGA MAF data. As both of the training set and testing set data were obtained from TCGA, the performance of MSIpred on the aforementioned testing set might be overoptimistic. We further decided to validate the performance of MSIpred with another 390-tumor testing set whose data were generated by non-TCGA projects. This 390-tumor testing set consisted of MAF files of 368 colorectal tumors 24 and 22 stomach tumors 25 . These MAF files and their corresponding binary (cBioPortal directly provided binary MSI status) MSI status determined by MSI-PCR were all obtained from cBioPortal 26, 27 . 90 of 390 tumors were determined as MSI-H and the rest 300 were determined as MSS by MSI-PCR. With this non-TCGA testing set, MSIpred achieved a sensitivity (recall) of 0.778, specificity of 0.990, precision of 0.959, G mean of 0.877, F1 score of 0.859, and overall accuracy of 0.941. Compared to the performance of MSIpred on the previous 358-tumor TCGA testing data, the sensitivity of MSIpred on non-TCGA testing data was lower, but still reached a good overall accuracy.
Comparison of MSIpred with MSIseq. Among previously published software tools, MSIseq 12 is the only one that also predicts MSI status solely from tumor MAF files. Our tool MSIpred also utilized nine mutation features that were first proposed by MSIseq. Therefore, we compared performances of MSIseq with MSIpred in this study. The 390-tumor non-TCGA testing set that was utilized to validate performance of MSIpred was also used to evaluate MSIseq with its default decision tree classifier. MSIseq gave overall accuracy of 0.918, sensitivity of 0.667, precision of 0.968 and specificity of 0.993 (see Table 3 ). These results revealed that MSIseq was good at recognizing negative samples (MSS) but poor at recognizing positive samples (MSI-H). Thus, MSIpred achieved higher sensitivity and accuracy than MSIseq. Supplementary Table S1 , row 1-9). Results showed that by adding 13 new features, performance of MSIpred was improved (see Table 3 ). The sensitivity of MSIpred was improved from 0.667 to 0.778 and overall accuracy was improved from 0.910 to 0.941.
Discussion
We utilized 22 features, which can be computed from tumor MAF files, to characterize somatic mutational load of tumors by considering both mutation types and their detailed translational/regulatory effects. All these 22 features were differentially distributed in MSI-PCR determined MSS and MSI-H tumors, indicating that these features could serve as useful predictors for MSI classification. Further analysis on these 22 features using a random forest classifier revealed that all these 22 features contributed to the classification of MSS and MSI-H tumors.
We then developed a python package called MSIpred, which implemented a SVM classifier trained by those 22 features of a 1074-tumor training set, and a bioinformatics pipeline to compute those required features from MAF files to perform automatic binary MSI classification. If more data is available for training, MSIpred allows redo of the training step in order to get a better classifier. Those MAF files that MSIpred utilized as inputs were generated from paired tumor-normal exome sequencing data. An evaluation of MSIpred by finding concordances with MSI-PCR determined MSI status on a 358-tumor testing set showed that MSIpred is a robust pan-tumor MSI classification tool with high accuracy, sensitivity, and specificity. Using MSI-PCR determined MSI status as the experimental reference, 6 discrepancies including five false negative cases and one false positive case were observed in MSIpred classification results. Further analysis of their somatic mutational load and mutation profiles in terms of genes belonging to MMR system revealed that three of five false negative tumors were likely to possess intact MMR systems, while the other two false negatives were likely to possess inactivated or insufficient MMR systems. The only false positive case was also likely to possess an inactivated or insufficient MMR system. These results all together revealed that some of the discrepancies may due to misclassification of MSI-PCR method when considering tumor mutation profiles (see Fig. 3 ). For those three false negatives with intact MMR systems and the only false positive case, their MSIpred predicted MSI status were more persuasive while for the rest two false negative cases, MSI-PCR termed MSI status were more likely to be correct. Thus MSIpred can serve as a reliable complementary tool for MSI diagnosis beyond the conventional MSI-PCR method. Besides, as MSIpred only requires MAF files for MSI classification, it enables researchers to better utilize NGS data from public domain.
Several computational tools for MSI classification based on NGS data were published. MSIsensor 10 and mSI-NGS 11 both examine aligned reads in "BAM" format, and try to derive MSI status by measuring prevalence of unstable microsatellite loci throughout genome. MOSAIC 13 is another software that utilizes sequencing data in "BAM" format for MSI classification. However, MOSAIC doesn't directly compare distributions of unstable microsatellite loci in paired tumor-normal data, instead, it implemented a weighted tree classifier to perform MSI classification using average gain of novel microsatellite alleles. BAM files are often very large and need large amount of computational resources to manipulate. Mutation calling has become a routine analysis for NGS data and yields tumor mutation data in MAF format. MSIseq 12 and MIRMMR 14 , two MSI classification tools that either solely or partially utilize MAF data for MSI classification have been released. MSIseq implemented a decision tree classifier using features computed from MAF files as well as a feature of tumor types, which would potentially limit its application to some rare tumors. In addition, MSIseq only makes use of general types of mutations (single nucleotide variants or micro-indels) without considering their translational and regulatory effects. Unlike MSIseq, which only requires MAF data, MIRMMR also requires additional tumor methylation data to predict MSI status by a logistic regression classifier. In our study, MSIpred incorporated 9 of 10 features (eliminated tumor type) proposed by MSIseq, and added another 13 features that take potential translational and regulatory effects of mutations into account. By applying MSIpred and MSIseq to another 390-tumor non-TCGA testing set, the good performance of MSIpred was further validated, though a decline in its sensitivity was observed. This underestimation of MSI using non-TCGA data could potentially be explained by that MMR genes can also be repressed by epigenetic mechanisms. Apart from that, MSIpred did not consider individual microsatellite locus when doing classification, but individual microsatellite locus might be informative in terms of MSI classification. Compared to MSIseq, MSIpred still reached a better sensitivity and overall accuracy. A modified MSIpred that only utilized 9 (the features previously utilized by MSIseq) of 22 features was also applied to the same non-TCGA packages to work properly. First, a MAF file is annotated by adding an additional column "In_repeats", indicating whether mutation events took place in simple sequence repeats region or not. The annotated MAF file generated by last step is then utilized to extract 22 features characterizing somatic mutational load for all tumors embedded in this annotated MAF file. These 22 features of all tumors are then combined into a feature matrix as a pandas dataframe. Finally, MSIpred calls the implemented SVM classifier to accurately predict tumor MSI status using the aforementioned feature matrix, and returns results as a pandas dataframe. MSIpred also allows users to train new SVM classifier given new MAF data and known MSI statuses of tumors. Subsequently, the newly trained SVM classifier can be utilized for MSI prediction. A general workflow of MSIpred is presented in Fig. 4 .
Somatic mutation data and clinical MSI status of tumors. MAF files of somatic mutation data created by MuTect mutation calling pipeline were collected from four projects (COAD: colon adenocarcinoma, READ: rectal adenocarcinoma, STAD: stomach adenocarcinoma, and UCEC: uterine corpus endometrial carcinoma) of TCGA [31] [32] [33] . MSI-PCR determined MSI status of all tumors were collected from tumor clinical data provided by TCGA. To retrieve these data from TCGA, a R package called TCGAbiolinks (version 2.5.12) 34 was used for data query in this study. In total, MAF files together with MSI-PCR determined MSI status of 1432 tumors (COAD: 377, READ: 131, STAD: 437, UCEC: 487) were used in this study.
Feature selection. We incorporated 9 features (see Supplementary Table S1 , row 1-9) proposed by MSIseq 12 . These nine features were calculated based on information of 'Variant_Type' columns of MAF files. These nine features take account mutations in simple sequence repeats region specially, thus we need a reference file for loci of simple sequence repeats region in human genome. We retrieved loci of simple sequence repeats for GRCh38 (Genome Reference Consortium Human Reference 38) from a table called "SimpleRepeats" in UCSC genome annotation database (http://hgdownload.cse.ucsc.edu/goldenPath/hg38/database/simpleRepeat.txt.gz). Although, typical unit lengths of microsatellites vary from one to six base pairs, but a recent study pointed out that microsatellite loci with long unit lengths cannot be detected reliably by using 100 bp (which is the reads length utilized by TCGA) sequencing reads 35 . Thus we only retrieved loci of simple sequence repeats whose unit lengths are less than and equal to five base pairs. Besides, we utilized another 13 features (see Supplementary  Table S1 , row [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , which were calculated from information of 'Variant_Classification' columns of MAF files. These 13 features gave more detailed information about potential translational and regulatory effects of mutations that can differentiate deleterious mutations from not deleterious ones. In general, all these 22 features denote counts of different kinds of mutations normalized by lengths (Mb) of captured exome sequences. For all 1432 tumors used in this study, their captured exome sequence lengths were obtained from their TCGA project marker papers (COAD: 44 Mb, READ: 44 Mb, STAD: 50 Mb, UCEC: 44 Mb) [31] [32] [33] .
Training and testing set. Features and corresponding MSI-PCR determined MSI status for all tumors were formulated into a large table (see Supplementary 1432_tumor_feature.csv). This table were then randomly split into two data sets, training and testing, according to a ratio of three to one for each tumor type, using a function called "train_test_split" provided by sklearn. Tables 1 and 2 shows the summary of these two datasets.
Analysis of 22 features regarding their importance in MSI classification.
We used the random forest algorithm to perform comprehensive analysis of all 22 features in order to gain their importance in MSI classification 23 . A random forest classifier was trained by the 1074-tumor training set using a random forest classifier framework provided by the python package scikit-learn (sklearn, 0.19.1) 30 . Importance scores of all features were then obtained from the "feature_importances_" attribute of the trained random forest classifier.
Categorization of MSI.
TCGA categorized MSI into three types using MSI-PCR: MSS (microsatellite stable), MSI-L (microsatellite instability low), and MSI-H (microsatellite instability high) in its clinical data. In this study, we grouped first two categories (MSS and MSI-L) together and denoted them as MSS because a recent study pointed out MSS and MSI-L tumors possess similar MSI burden 13 . We denoted MSI-H tumors as positive samples and MSS tumors as negative samples to make it more convenient for binary classification and model evaluation.
Non-TCGA testing set. MAF files of 390 tumors, including 368 colorectal tumors and 22 stomach tumors generated by two non-TCGA projects 24, 25 together with their corresponding clinical data that embedded MSI-PCR determined binary (MSS and MSI-H) tumor MSI status, were directly downloaded from cBioPortal 26, 27 . 22 features for mutational load characterization of each of these 390 tumors (see Supplementary non_ tcga_390_tumor.csv) were extracted by MSIpred from their MAF files. Corresponding captured exome lengths (colorectal: 67 Mb, stomach: 38 Mb) required by MSIpred were obtained from their corresponding papers 24, 25 . This data set was denoted as non-TCGA testing set, which was aimed to validate performance of MSIpred, and to conduct comparisons among original MSIpred (22 features), modified MSIpred (9 features), and MSIseq (10 features).
Support vector machine.
Support vector machines (SVMs) have been widely used in classification problems of computational biology due to high accuracy and flexibility in statistical modeling 36 . In this study, we utilized a SVM framework provided by the python package scikit-learn (sklearn, 0.19.1) 30 to build our binary (MSS and MSI-H) classifier. As support vector machine is sensitive to scaling of features, our classifier actually was designed to incorporate a two-step framework: the first step is a standardized scaler provided by StandardScaler class of sklearn for feature normalization; the second step is a support vector machine classifier. A radial basis function (RBF) kernel of SVM was chosen and hyper parameters, gamma and C were tuned with 1074-tumor training data using grid search paired with ten-fold cross validation, which was achieved using GridSearchCV function of sklearn. The hyper parameter set yielding the largest average accuracy during cross validation was chosen. The SVM framework with optimized hyper-parameters was then trained with all training data (1074 tumors), and this trained SVM classifier was embedded in MSIpred.
Model assessment metrics. As our 358-tumor testing set is imbalanced (280 MSS (negative) and 78 MSH(positive)), it is not sufficient to evaluate performance of our classifier by just using overall accuracy. Thus, we incorporated several other metrics for model evaluation. Equations of these metrics are given with following abbreviations: sensitivity (Se), specificity (Sp), precision (Pre), accuracy (ACC), FP (False Positive), FN (False Negative), TP (True Positive), TN (True Negative). Receiver operating characteristic (ROC) curve and precision-recall curve were plotted to visualize the performance of MSIpred. Coordinate data used for plotting precision-recall curve and ROC curve was obtained by "precision_recall_curve" function and "roc_curve" function provided by sklearn, respectively. Visualizations were achieved using Matplotlib package.
Comparisons among original MSIpred, modified MSIpred and MSIseq. We compared performances of our original MSIpred (22 features) with a modified version of MSIpred (9 features) and MSIseq (10 features) using the aforementioned 390-tumor non-TCGA testing dataset. The simple sequence repeats reference file required by these three tools was based on the same human reference genome (i.e., GRCh37) that the testing MAF files were based on. The modified MSIpred implemented a MSI classifier that was trained by just 9 (see Table S1 row 1-9) of 22 features of all tumors from the 1074-tumor training set. Performance comparisons of the original MSIpred, modified MSIpred and MSIseq were conducted by using aforementioned metrics.
Statistical analysis.
Wilcoxon rank sum tests were conducted using a built-in R (version 3.4.3) function wilcox.test. Data visualization was achieved using R package ggplot2 (version 2.2.1) 37 , python package Matplotlib (version 2.0.2) 38 , and python package Seaborn (version 0.8.0) 39 .
Availability
MSIpred is written in python 2. The package and detailed usage documents are freely available on GitHub: (https://github.com/bioinfolabmu/MSIpred). All the datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
